In vivo staging of regional amyloid deposition
Institute for Neurodegenerative Disorders · Athinoula A. Martinos Center for Biomedical Imaging · +2 more institutions
Abstract
To estimate a regional progression pattern of amyloid deposition from cross-sectional amyloid-sensitive PET data and evaluate its potential for in vivo staging of an individual's amyloid pathology.Multiregional analysis of florbetapir (18F-AV45)-PET data was used to determine individual amyloid distribution profiles in a sample of 667 participants from the Alzheimer's Disease Neuroimaging Initiative cohort, including cognitively normal older individuals (CN) as well as patients with mild cognitive impairment and Alzheimer disease (AD) dementia. The frequency of regional amyloid positivity across CN individuals was used to construct a 4-stage model of progressing amyloid pathology, and individual distribution…
Citation impact
- FWCI
- 13.35
- Percentile
- 100%
- References
- 40
Authors
8- MJMichel J. GrotheCorresponding
Institute for Neurodegenerative Disorders, Athinoula A. Martinos Center for Biomedical Imaging, University of Rostock, Leipzig University
- HBHenryk Barthel
Institute for Neurodegenerative Disorders, Athinoula A. Martinos Center for Biomedical Imaging, University of Rostock, Leipzig University
- JSJorge Sepulcre
Institute for Neurodegenerative Disorders, Athinoula A. Martinos Center for Biomedical Imaging, University of Rostock, Leipzig University
- MDMartin Dyrba
Institute for Neurodegenerative Disorders, Athinoula A. Martinos Center for Biomedical Imaging, University of Rostock, Leipzig University
- OSOsama Sabri
Institute for Neurodegenerative Disorders, Athinoula A. Martinos Center for Biomedical Imaging, University of Rostock, Leipzig University
Topics & keywords
- In vivo
- Amyloid (mycology)
- Pathology
- Deposition (geology)
- Amyloid β
- Medicine
- Chemistry
- Neuroscience
Funding
- UDU.S. Department of DefenseAwards: U01 AG024904, W81XWH, W81XWH-12-2-, W81XWH-12-2-0012, AG024904
- FFFoundation for the National Institutes of HealthAwards: W81XWH-12-2-0012, AG024904, U01 AG024904
- AAAlzheimer's AssociationAwards: U01 AG024904, W81XWH-12-2-0012
- BSBristol-Myers SquibbAwards: U01 AG024904, AG024904, W81XWH-12-2-0012
- ELEli Lilly and CompanyAwards: U01 AG024904, AG024904, W81XWH-12-2-0012
- PPfizerAwards: AG024904, W81XWH-12-2-0012, U01 AG024904
- BBiogenAwards: W81XWH-12-2-0012, U01 AG024904, AG024904
- UOUniversity of Southern CaliforniaAwards: W81XWH-12-2-0012, U01 AG024904
- FHF. Hoffmann-La RocheAwards: W81XWH-12-2-0012, AG024904, U01 AG024904
- MSMeso Scale DiagnosticsAwards: U01 AG024904, AG024904, W81XWH-12-2-0012
- ADAlzheimer's Disease Neuroimaging InitiativeAwards: AG024904, W81XWH-12-2-, W81XWH-12-2-0012, Department of Defense award number W81XWH-12-2-0012, U01 AG024904
- BBioClinicaAwards: U01 AG024904, W81XWH-12-2-0012, AG024904
- NPNovartis Pharmaceuticals CorporationAwards: W81XWH-12-2-0012, U01 AG024904, AG024904
- NCNorthern California Institute for Research and EducationAwards: U01 AG024904, W81XWH-12-2-0012
- EEisaiAwards: W81XWH-12-2-0012, U01 AG024904, AG024904
- DZDeutsches Zentrum für Neurodegenerative Erkrankungen
- SServierAwards: AG024904, W81XWH-12-2-0012, U01 AG024904
- HLH. Lundbeck A/SAwards: U01 AG024904, AG024904, W81XWH-12-2-0012
- IIXICOAwards: AG024904, W81XWH-12-2-0012, U01 AG024904
- NINational Institutes of HealthAwards: AG024904, U01 AG024904, W81XWH, W81XWH-12-2-0012
- GGenentechAwards: W81XWH-12-2-0012, AG024904, U01 AG024904
- UOUniversity of California, San Diego
- CICanadian Institutes of Health ResearchAwards: U01 AG024904, W81XWH-12-2-0012
- NINational Institute on AgingAwards: U01 AG024904, W81XWH-12-2-0012, AG024904
- NINational Institute of Biomedical Imaging and BioengineeringAwards: W81XWH-12-2-0012, U01 AG024904, AG024904